Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease.

American journal of hematology - 1 Mar 2008

Darbari Deepika S, van Schaik Ron H N, Capparelli Edmund V, Rana Sohail, McCarter Robert, van den Anker John

Abstract excerpt

The purpose of the study was to determine if UDP-glucuronosyltransferase (UGT) 2B7 allelic variants encoding for UGT2B7, primary enzyme responsible for morphine glucuronidation contribute to the variability in the hepatic clearance of morphine in sickle cell disease (SCD). Twenty-four hour PK study of morphine and UGT2B7 variants genotyping was performed in 20 SCD patients in a steady state of health. Presence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Sickle Cell
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cross-Sectional Studies

Share to Glucuronosyltransferase

Share to Liver Function Tests

Share to Metabolic Clearance Rate

Share to Morphine

Source

Identifiers

PMID: 17724700
DOI: 10.1002/ajh.21051

Genes

SCD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease.PMID 17724700Read ↗

Pharmacogenetics of morphine: Potential implications in sickle cell disease.Semantic proximity Read ↗

Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in African American children with sickle cell disease.Semantic proximity Read ↗

The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease.Semantic proximity Read ↗

Variability in UDP-glucuronosyltransferase genes and morphine metabolism: observations from a cross-sectional multicenter study in advanced cancer patients with pain.Semantic proximity Read ↗

A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine.Semantic proximity Read ↗

Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients.Semantic proximity Read ↗

Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene.Semantic proximity Read ↗

Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy.Semantic proximity Read ↗

A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity.Semantic proximity Read ↗

Pharmacogenetics of Pain Management in Zimbabwean Patients With Sickle Cell DiseaseSemantic proximity Read ↗

Tramadol-related fatalities: Metabolic ratios & SNPs/INDELs belonging to UGT1A8, UGT2B7, ABCC2, and SLC22A1.Semantic proximity Read ↗

Genetic variability and clinical efficacy of morphine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.